RxDoctor Payments Data

Henry Purvis, MD

Family Medicine · Statesboro, GANPI 1780687954

Payments from drug & device makers

$9,331in general payments, 2019–2025

Across 563 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Novo Nordisk$835
  • AstraZeneca$736
  • Pfizer$541
  • Boehringer Ingelheim$541
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$9,331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,331 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$95,773
Medicare patients
337
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin207$197,420
OzempicSemaglutide89$106,273
EliquisApixaban134$98,065
HumiraAdalimumab12$83,496
MounjaroTirzepatide52$62,712
RybelsusSemaglutide51$56,773
TrulicityDulaglutide55$56,749
XareltoRivaroxaban38$45,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$43,529
VascepaIcosapent Ethyl61$38,920
KerendiaFinerenone49$35,379
LinzessLinaclotide37$28,502
Repatha SureclickEvolocumab44$26,790
FarxigaDapagliflozin Propanediol35$23,772
JanuviaSitagliptin Phosphate28$22,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$541$197,420207 claims
Novo NordiskOzempic, Rybelsus$835$163,045140 claims
Lilly USA, LLCMounjaro, Trulicity$536$119,462107 claims
AbbVieHumira, Linzess, Synthroid$1,114$117,32192 claims
PfizerEliquis$541$98,065134 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$140$56,580113 claims
Johnson & JohnsonXarelto$38$45,92238 claims
MerckJanuvia, Janumet Xr, Belsomra$175$45,58666 claims
BayerKerendia$417$35,37949 claims
Sumitomo Pharma America, Inc.Gemtesa, Myfembree$12$29,74747 claims
AstraZenecaFarxiga$736$23,77235 claims
NovartisEntresto$237$18,86624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →